Investment Thesis
Exousia Bio exhibits terminal revenue decline (-67.4% YoY to $0.00) combined with zero cash reserves and significant operating losses (-$268.8K), indicating severe business deterioration and imminent solvency risk. While low debt levels ($261K vs $21.8M equity) provide minimal buffer, the complete absence of revenue generation and liquidity create an untenable financial position requiring fundamental restructuring.
Strengths
- Low debt burden with only $261K liabilities against $21.8M stockholders equity
- Positive operating cash flow of $176.6K despite negative net income
- Minimal leverage reduces immediate default risk relative to equity cushion
Risks
- Zero revenue with -67.4% YoY decline indicates business model failure or collapse
- Zero cash and equivalents creates critical liquidity crisis and imminent insolvency risk
- Operating losses of $268.8K while generating no revenue demonstrates unsustainable burn rate
- Contradictions between reported cash flow and zero cash balance suggest data quality issues
- Zero Form 4 insider filings in 90 days indicates loss of insider confidence
- Non-revenue generating company in educational services sector lacks clear path to profitability
Key Metrics to Watch
- Quarterly revenue generation and return to positive sales
- Cash position and monthly cash burn rate relative to equity reserves
- Operating expense control and path to break-even operations
- Customer acquisition metrics and revenue per customer trends
Financial Metrics
Revenue
0.0
Net Income
-50.9K
EPS (Diluted)
$0.00
Free Cash Flow
176.0K
Total Assets
22.1M
Cash
0.0
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-0.2%
ROA
-0.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.00x
Quick Ratio
0.00x
Debt/Equity
0.00x
Debt/Assets
1.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T16:54:24.307745 |
Data as of: 2025-11-30 |
Powered by Claude AI